First-in-man randomised comparison of a novel sirolimuselutingstent with abluminal biodegradable polymer and thinstrutcobalt-chromium alloy: INSPIRON-I trial

Ribeiro, Expedito E; Campos, Carlos M; Ribeiro, Henrique B; Lopes, Augusto C; Esper, Rodrigo B; Meirelles, George X; Perin, Marco A; Abizaid, Alexandre; Lemos, Pedro A.
EuroIntervention ; 09: 1380-1384, 2013. ilus
Artículo en Inglés | SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1062681

Documentos relacionados

  1. Scoring model to predict low image quality of drug-eluting stent evaluated by computed tomography coronary angiography.
  2. Is Coronary Brachytherapy Staging a Comeback for the Treatment of In-Stent Restenosis?
  3. [Advances in Preparation and Evaluation of Non-vascular Drug-eluting Stents].
  4. Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis.
  5. Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting Balloons, a Real-Life Single-Centre Study.
  6. Factors Associated with Coronary In-Stent Restenosis after Drug-Eluting Stent Implantation in Patients on Chronic Hemodialysis.
  7. Is coronary artery tortuosity a predisposing factor for drug-eluting stent restenosis?
  8. [The Incidence and Possible Predictors of Coronary Restenosis].
  9. Failure patterns after intravascular brachytherapy for in-stent coronary restenosis.
  10. Angiographic performance of everolimus-eluting stents for the treatment of coronary in-stent restenosis in daily practice.